Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
79 hedge funds and large institutions have $545M invested in Akero Therapeutics in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
18% more funds holding
Funds holding: 67 → 79 (+12)
17% more capital invested
Capital invested by funds: $468M → $545M (+$77.5M)
0.86% less ownership
Funds ownership: 77.1% → 76.24% (-0.86%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
76% less call options, than puts
Call options by funds: $206K | Put options by funds: $869K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.08M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.33M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$3.78M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.15M |
| 5 |
Morgan Stanley
New York
|
+$3.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$14.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$6M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.96M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$4.05M |
AKRO Hedge Fund Activity: Q2 2020 in Review
79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2020, worth a combined $545M — up 17% from $468M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AKRO positions and 8 closed out — a net gain of 12 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $7.08M. The largest seller was Versant Venture Management, cutting an estimated $14.2M.
- 79 institutional investors held Akero Therapeutics (AKRO) as of Q2 2020, up from 67 in Q1 2020.
- Funds reported $545M of Akero Therapeutics stock for Q2 2020, up 17% quarter-over-quarter.
- 20 funds opened new Akero Therapeutics positions in Q2 2020 and 8 closed out, a net change of +12 holders.
- The largest Akero Therapeutics buyer in Q2 2020 was BlackRock, an estimated $7.08M added.
- The largest Akero Therapeutics seller in Q2 2020 was Versant Venture Management, an estimated $14.2M sold.
Based on aggregated 13F filings for Q2 2020.